Rami Elghandour, Arcellx CEO
FDA lifts partial hold on Arcellx’s Gilead-partnered blood cancer cell therapy as biotech aims for 2026 launch
Arcellx’s Gilead-partnered multiple myeloma cell therapy is in the clear, as the FDA has removed the partial clinical hold it placed on the CAR …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
